Cullinan Therapeutics, Inc. (CGEM) is a publicly traded company in the Healthcare sector, operating within the Medical - Pharmaceuticals industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Nadim Ahmed.
CGEM has IPO date of 2021-01-08, 111 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $868.55M.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
